MAPT and Alzheimer disease: The initial findings demonstrated a significant reduction in the protein levels of phosphorylated tau at sites p‐S396, p‐S356, and Thr231 in the hippocampus and cortex at the low‐dose gastrodin treatment compared to the AD control group.